Search

1-benzylimidazole

1-benzylimidazole, an N-imidazole derivative, has been shown to have strong cardiotonic activity.

Ochromycinone

Ochromycinone is under investigation in clinical trial NCT01047943 (STA-21 Topical Efficacy on Psoriasis).

ARCT-810

ARCT-810 is an mRNA replacement therapy that delivers ornithine transcarbamylase mRNA to hepatocytes.

EB05

EB05, in combination with standard of care (SOC), is being investigated in clinical trial NCT04401475 to evaluate its safety and efficacy in adult hospitalized patients with COVID-19 and ARDS.

Ingenol disoxate

Ingenol disoxate is under investigation in clinical trial NCT02120456 (Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk

Altropane I-123

Altropane I-123 is under investigation in clinical trial NCT01950468 (A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the

Vatalanib

Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.

Obinepitide

These hormones are known to play a role in the regulation of food intake and appetite in man as satiety signal from the GI-tract to the CNS.

SB-743921

Cabozantinib

Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor.